V-Bio Ventures portfolio company Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic Use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting TNFR2, as well as its […] May 15, 2023 · V-Bio Ventures
University Hospital Ghent and VIB are testing medication to treat COVID-19-associated respiratory illness University Hospital Ghent and VIB are assessing a drug called Leukine® to treat patients with respiratory illness associated with COVID-19. Major medical centers in [...] March 25, 2020 · BioVox
Belgian clinical trials for COVID-19 With COVID-19 cases soaring into the millions, and a vaccine still a ways off, patients are desperate for a treatment. […] May 5, 2020 · BioVox
Cell therapies: opportunities and challenges Recent activities in the cell therapy field have prompted many investment funds to pour fresh and increasing capital into this […] May 5, 2020 · V-Bio Ventures
Fundamental research leads to treatment breakthrough in rare genetic diseases A basic research breakthrough is improving patient lives, as researchers realized their rare genetic condition could be treated by repurposing […] June 8, 2020 · BioVox
The opioid epidemic: solutions to a painful problem Opioid misuse is a public health crisis that has resulted in debilitation, deaths, and significant social and economic impact. The […] July 7, 2020 · V-Bio Ventures
V-Bio invests into ExeVir Bio to accelerate development of new treatment conferring broad protection against Covid-19 Ghent, Belgium, 28 July 2020 – Today V-Bio Ventures announces its investment in a EUR 23 million Series A financing into ExeVir Bio. […] July 28, 2020 · V-Bio Ventures
Biodol Therapeutics receives EUR 4.5 million to progress its novel pain medication in a Series A led by V-Bio Ventures V-Bio Ventures, a leading Belgian life sciences VC, invests in Biodol Therapeutics, a French biotech specialized in next-generation chronic pain […] August 31, 2020 · V-Bio Ventures
Drug combos: how much is 1 + 1? Many of our current antiviral, antibacterial and anti-tumour medications are comprised of combinations of two or three active substances, selected […] August 31, 2020 · V-Bio Ventures
Belgian stem cell company GST bought by German pharmaceutical giant The German pharmaceutical giant Boehringer Ingelheim has acquired GST, a stem cell specialist based in Belgium. A part of the […] August 31, 2020 · Turnstone Communications
A novel approach to neurology could bring relief to people in pain In August 2020, V-Bio Ventures announced their investment in Biodol Therapeutics, a French start-up looking to make a difference to […] August 31, 2020 · V-Bio Ventures
Countering COVID-19 with llama antibodies In July 2020, VIB spin-off ExeVir Bio raised €23 million to advance a llama-derived antibody against COVID-19. The company is […] August 31, 2020 · BioVox
UAntwerp researchers find cause for mysterious nodding syndrome For decades, researchers have been trying to uncover the cause of nodding syndrome, a mysterious and deadly form of epilepsy […] September 30, 2020 · BioVox
V-Bio Ventures invests in new start-up Animab in a EUR 3.4 million Seed Financing to improve health and performance of livestock animals Gent, Belgium, 27 October 2020 – Today V-Bio Ventures announces its investment in Animab, a new venture spin-off from VIB, in a EUR […] October 27, 2020 · V-Bio Ventures
An insightful solution to eye injections Developing new therapies is sometimes not enough: for retinal indications, accurate delivery is key to making a drug work. Lowering […] November 4, 2020 · V-Bio Ventures